Skip to content

Stimulant effects of 3,4‐methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal

J. G. Ramaekers, K. P. C. Kuypers, N. Samyn

Addiction August 8, 2006 DOI: 10.1111/j.1360-0443.2006.01566.x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Double-blind, placebo-controlled, three-way crossover study Peer reviewed
Sample size 18
Population Recreational MDMA users aged 21–39 years
Interventions MDMA methylphenidate
Dose 75 mg
Duration Driving tests conducted 3-5 hours post-drug (intoxication phase) and 27-29 hours post-drug (withdrawal phase)
Topics MDMA
Keywords Stimulant Methylphenidate Placebo Anesthesia Poison control Methamphetamine Hallucinogen Dextroamphetamine
Citations 90
Key points MDMA improved road-tracking but impaired car-following performance during intoxication, with no effects during withdrawal.

Abstract

ABSTRACT Background 3,4‐methylenedioxymethamphetamine (MDMA) is currently one of the most popular drugs of abuse in Europe. Its increasing use over the last decade has led to concern regarding possible adverse effects on driving. The aims of the present study were to investigate the acute effects of MDMA on actual driving performance during the intoxication and withdrawal phase.

Methods: Eighteen recreational MDMA‐users (nine males, nine females) aged 21–39 years participated in a double‐blind, placebo‐controlled, three‐way cross‐over study. MDMA 75 mg, methylphenidate 20 mg and placebo were administered on day 1 of treatment (intoxication phase). Driving tests were conducted between 3 and 5 hours post‐drug. Subjects returned the following day for a repetition of the driving tests between 27 and 29 hours post‐drug (withdrawal phase). On‐the‐road driving tests consisted of a road‐tracking test and a car‐following test. Its main parameters were standard deviation of lateral position (SDLP), time to speed adaptation (TSA), brake reaction time (BRT) and gain.

Findings: MDMA and methylphenidate significantly decreased SDLP in the road‐tracking tests by about 2 cm relative to placebo on day 1 (intoxication phase). In addition, MDMA intoxication decreased performance in the car‐following test as indicated by a significant rise in the ‘overshoot’ of the subjects’ response to speed decelerations of the leading vehicle. Driving performance was not affected by treatments during withdrawal on day 2.

Conclusion: Collectively, these data indicate that MDMA is a stimulant drug that may improve certain aspects of the driving task, such as road‐tracking performance, but may reduce performance in other aspects of the driving task, such as accuracy of speed adaptation during car‐following performance.

Comparable studies

Other randomized controlled trials on MDMA, most cited first.

Study Year Design Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Patients with severe PTSD, including those with comorbidities such as dissociation,... 2021 Randomized controlled trial n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Patients with treatment-resistant PTSD 2012 Randomized controlled trial n = 12
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Adults with moderate to severe post-traumatic stress disorder 2023 Randomized controlled trial n = 104

Citations in the library

Cited by 19

and 14 more in the library

Cites 11

and 6 more in the library

Explore topics